Acer Therapeutics (US, Private)

Acer is developing therapies for orphan diseases and needed more capital to advance its programs and to become an attractive acquisition target for strategic buyers and/or a candidate for cross over funding prior to public listing

Acer hired Extera to lead its corporate development function. Extera prepared all required materials, and outreached to top decision makers at companies interested in the orphan space, as well as financial investors. These efforts resulted in an equity financing into Acer by TVM and other investors as well as strong ongoing relationships with potential strategic buyers.

$12m equity financing